NNC0165-1273 reduces nocturnal food intake, attenuates feeding behavior, induces early satiety, and causes dose-dependent decreases in body weight and fat mass in diet-induced obese mice
Your GP, diabetes specialist nurse, and consultant should work collaboratively to optimise your treatment plan
Reviewed by: FormBlends Medical Team | Last updated: May 29, 2026 | Sources: USP general chapters, FDA compounding guidance, peer-reviewed GLP-1/GIP pharmacology literature, manufacturer prescribing information
Ludwig, MD, PhD Harvard Medical School After 15 years of research in partnership with experts from Stanford and UCLA, we developed BuildLeaf as a safer, more effective evolution of Tirzepatide
Key GLP-1 Receptor Agonist Cardiovascular Outcome Trials Why Do GLP-1 Medications Protect the Heart
One common complication of these conditions is heart failure with preserved ejection fraction (HFpEF), a condition with a poor prognosis and life-limiting symptoms